Melanotan 2 in research

A PubMed search for melanotan returns a few hundred papers, and many more use the abbreviation MTII. Only a small share study the peptide for its own sake. Most use it as a dependable way to activate melanocortin receptors within a larger experiment, a distinction worth keeping in mind when reading claims about it online.

Receptor pharmacology

• Binding profile (Peptides, 1997): on cells expressing the human MC1, MC3, MC4 and MC5 receptors, the cyclic lactam MT-II bound all four with high affinity. Swapping its D-Phe for D-naphthylalanine shifted the balance towards MC4R.
• From agonist to antagonist (J Med Chem, 1995): placing bulky aromatic amino acids at position 7 produced SHU9119, which blocks MC3R and MC4R while still activating MC1R and MC5R.
• A recommended tool compound (ACS Pharmacol Transl Sci, 2024): a review of the field lists MT-II with NDP-MSH and SHU9119 as core reference ligands, used to validate receptor cell lines, as benchmarks in screening and in cryo-EM structural work.

Brain and behaviour in animals

• Melanocortin tone (Nature, 1997): injected into the brain ventricles of mice, MT-II reduced feeding in several models, and SHU9119 cancelled that effect. The study helped establish that brain MC4R signalling acts as a constant brake and explained the obesity of mice carrying the agouti mutation.
• Social bonding (Neuropsychopharmacology, 2015): in prairie voles, peripherally given MT-II promoted partner preference, an effect that depended on oxytocin signalling. The authors presented it as a lead for studying social behaviour, not as a treatment.

Studies in people

Planned human studies are few, small and mostly from the 1990s. The 1996 pilot phase 1 study enrolled three men and was designed to look at tolerability; it reported nausea, fatigue and sleepiness at higher levels, stretching and yawning, and pigment changes. Two small placebo-controlled crossover studies by the same group then examined erectile responses in men (1998 and 2000). None of this progressed into the large trials that approval requires.

In October 2026, ClinicalTrials.gov listed a single recruiting phase 2 study, sponsored by a company in China, testing Melanotan 2 alongside UVB light therapy in the skin condition vitiligo. No results have been posted.

Case reports

Much of what is known about Melanotan 2 in people now comes from doctors describing patients who bought it online. Such reports cannot prove cause and effect, but they show which problems turn up. They are summarised on the rules and safety page.

Reading the evidence

• Tool, not treatment: a compound that reliably activates a receptor in a mouse is valuable for science, but that alone says nothing about benefit in people.
• Non-selective by design: because MT-II hits several receptors at once, its effects in animals are hard to pin to one receptor, which is why more selective compounds have replaced it for many questions.
• Old, small human data: the pilot studies of the 1990s were not built to measure safety over time.
• Product uncertainty: material sold online may not match the peptide used in published studies.

Bottom line

In the laboratory, Melanotan 2 is a well-characterised reference agonist with decades of use in receptor and brain research. As a substance for people it remains unapproved and largely unstudied.

References

1. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754-5758. PMID 6777774
2. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. 1989;32(12):2555-2561. PMID 2555512
3. Hruby VJ, Lu D, Sharma SD, et al. Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5,D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem. 1995;38(18):3454-3461. PMID 7658432
4. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. PMID 8637402
5. Schiöth HB, Muceniece R, Mutulis F, et al. Selectivity of cyclic [D-Nal7] and [D-Phe7] substituted MSH analogues for the melanocortin receptor subtypes. Peptides. 1997;18(7):1009-1013. PMID 9357059
6. Fan W, Boston BA, Kesterson RA, et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-168. PMID 8990120
7. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. PMID 9679884
8. Wessells H, Gralnek D, Dorr R, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000;56(4):641-646. PMID 11018622
9. Modi ME, Inoue K, Barrett CE, et al. Melanocortin receptor agonists facilitate oxytocin-dependent partner preference formation in the prairie vole. Neuropsychopharmacology. 2015;40(8):1856-1865. PMID 25652247
10. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48-59. PMID 26132941
11. Weirath NA, Haskell-Luevano C. Recommended tool compounds for the melanocortin receptor (MCR) G protein-coupled receptors (GPCRs). ACS Pharmacol Transl Sci. 2024;7(9):2706-2724. PMID 39296259
12. ClinicalTrials.gov. Melanotan II (MT-II) as an adjunct to NB-UVB phototherapy for repigmentation in stable nonsegmental vitiligo. NCT07437560 (accessed 8 October 2026). NCT07437560